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S U M M A R Y
Objectives: To assess the performance of microscopic stool examination, which is used widely for the
diagnosis and assessment of infection rates of Schistosoma mansoni in Egypt, for the evaluation of
chemotherapy efﬁcacy after a decade of regular mass treatment.
Methods: A total of 651 individuals from Lower Egypt (55 children and 596 adults) were examined for S.
mansoni ova by microscopic stool examination (MSE) alone (n = 166; 111 adults and 55 children), rectal
biopsy (RB) alone (n = 32 adults), or both MSE and RB (n = 453 adults).
Results: Infection detection rates were signiﬁcantly lower in the MSE alone group (9%; 15/166)
compared to the RB alone group (40.6%; 13/32) and to the RB+MSE group (37.7%; 171/453). Out of all
positive cases in the MSE+RB group, only 23/171 patients (13.5%) were positive by stool examination, of
whom 21 were also positive by RB, in contrast to 169/171 patients (86.5%) positive by RB in the same
group. It was noted that adding MSE to RB did not increase the prevalence compared to RB alone: 37.3% in
the MSE+RB group vs. 40.6% in the RB only group. Using the summation of both MSE and RB tests as the
gold standard, the sensitivity of MSE was signiﬁcantly lower than that of RB: 13.5% vs. 98.8%.
Conclusions: The implementation of mass treatment programmes has resulted in a new era of light
infection, for which conventional parasitological methods for the diagnosis and monitoring of infection
can miss many patients.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Schistosomiasis, also known as bilharziasis, has been and
remains one of the most prevalent parasitic diseases worldwide. It
affects millions of people in the developing world, mainly in Africa,
and has substantial public health and economic impacts.1 Egypt is
one of the major countries affected by schistosomiasis. It has been
an area endemic for schistosomiasis since at least the Middle
Kingdom period (1500 BC).2 Early in the 20th century, between
1932 and 1934, Scott performed a wide-ranging survey of two
million individuals in government treatment centres and a house-
to-house survey of 40 000 subjects throughout rural areas in Egypt.
He found the prevalence of infection of both Schistosoma* Corresponding author. Current address: Epsom and St Helier NHS Trust, Wrythe
Ln, Carshalton, Surrey SM5 1AA, UK. Tel.: +44 (0)7883 410748.
E-mail address: yassherif@hotmail.com (Y. Elsherif).
http://dx.doi.org/10.1016/j.ijid.2015.10.023
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).haematobium and Schistosoma mansoni to be equally about 60%
in the rural population residing north and east of the Nile Delta.3
About 15 years ago, the Egyptian Ministry of Health and the
United States Agency for International Development (USAID)
performed a huge schistosomiasis research project investigating
the prevalence and intensity of infection of Schistosoma species.4
As part of the study, they collected stool samples from governor-
ates in Lower Egypt (Kafr El-Sheikh, El-Gharbia, El-Menouﬁa, El-
Qalubia, and El-Ismailia) almost exclusively endemic for S.
mansoni. The total screened population was 49 950. Quantitative
microscopic counting of Schistosoma ova in the stool using the
modiﬁed Kato technique was performed to diagnose these
patients. Results showed that the prevalence ranged from 17.5%
to 42.9%, with an average of 36.4%. Males had higher infection rates
and ova counts than females in all age groups.
In 2001, the World Health Assembly adopted Resolution 54.19,
which set a global target for all endemic countries for the year
2010. The World Health Organization (WHO) strategy for
schistosomiasis control was based on regular mass treatmentciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Prevalence of Schistosoma mansoni in all patients’ groups
Test performed No. of
patients (F/M)
Positive
cases (F/M)
Adults Group 1: MSE only 111 (43/68) 13 (2/11)
Group 2: RB only 32 (9/23) 13 (4/9)
Group 3: RB + MSE 453 (106/347) 171 (23/148)
Stool positive = 23 (9/14)
Rectal biopsy
positive = 169 (23/146)
Children Group 4:
MSE only
55 (27/28) 2 (0/2)
Total 651 (185/466) 199 (29/170)
F, female; M, male; MSE, microscopic stool examination; RB, rectal biopsy.
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and effective drugs, which made it feasible to implement large-
scale preventive chemotherapy. Many countries beneﬁted from
the WHO treatment programme, including Brazil, Burkina Faso,
Cambodia, China, Mauritius, Morocco, Oman, and Saudi Arabia. As
for many other countries, the WHO strategy was endorsed by the
Egyptian Ministry of Health. It authorized the distribution of
praziquantel to high-risk individuals even prior to laboratory
diagnosis. Praziquantel became available free of charge in almost
all primary care units, including general practice centres, and at a
cheap price even over the counter. The media has played a major
role in population awareness about this treatment.
The outcome appeared excellent. In El-Beheira Governorate,
one of the most endemic areas in the Nile Delta, the prevalence of
schistosomiasis was reduced from 26% in 1996 to 3.8% in 2003.5 In
2003, the mass distribution of praziquantel targeting mainly
school children was continued and achieved a further reduction in
prevalence to 1.9% in 2007.6
More recently, however, the long-term beneﬁts of this strategy
have been the subject of debate. Estimates of the prevalence of
schistosomiasis have relied on the use of well-established, but
imperfect, diagnostic tests.7 The main method used to diagnose
these patients has been simple microscopic stool examination
(MSE), which has several drawbacks in the process of diagnosing S.
mansoni due to the daily variations in egg excretion levels and the
intensity of infection. MSE has been shown to have low sensitivity
in cases with light infection.6
The use of diagnostic assays with a low sensitivity and/or
speciﬁcity can be misleading in the evaluation of schistosomiasis
control programmes, such as those aimed at morbidity reduction
through mass human chemotherapy. This study was designed to
assess the performance of parasitological microscopy, which is used
widely for the diagnosis of active infection and infection rates in Egypt,
after a decade of regular mass chemotherapy of schistosomiasis.
2. Subjects and methods
This study was conducted and coordinated by the National Liver
Institute, Menouﬁa University, Egypt. The National Liver Institute
is located in Menouﬁa Governorate, in the middle of the Nile Delta
region of Egypt, which is a well-known endemic area for S. mansoni
infection. Individuals were recruited from nine villages of three
governorates in the Nile Delta region: Menouﬁa, El-Gharbia, and
El-Beheira. All children included in the study were recruited from
Al-Raheb village primary school, Menouﬁa Governorate, through a
collaborative work with the Al-Raheb General Practice Medical
Unit, Egyptian Ministry of Health.
Individuals from rural areas with a history of continuous canal
water contact suggesting a risk of infection were included. However,
none of them was clinically symptomatic. All individuals were
screened for S. mansoni. They were divided into groups according to
age and the method of diagnosis. Adults were classiﬁed into three
groups: group 1 had MSE only, group 2 had a rectal biopsy (RB) only,
and group 3 had both MSE and RB. All children were allocated to
group 4 and underwent MSE only (Table 1).
Full history-taking and a complete clinical examination were
performed by a consultant and/or hepatology registrar to exclude
any manifestation of hepatic decompensation, deﬁned as clinical
evidence and/or a history of bleeding oesophageal varices, hepatic
encephalopathy, jaundice, prolonged prothrombin time, or ascites.
2.1. Diagnosis of Schistosoma mansoni
Two different procedures were used to diagnose active
infection: (1) simple microscopic stool examination, and (2) rectal
biopsy. Some patients had only one procedure, while others hadboth (Table 1). The RB technique was not used for children.
Praziquantel therapy was offered to all Schistosoma-infected cases.
2.2. Microscopic stool examination (MSE)
The conventional method was employed for the examination of
stool samples: simple stool sedimentation by centrifugation
followed by detection under a microscope with a 10 objective
lens; any entity seen was then further conﬁrmed with a 40
objective lens. The test was considered positive if ova were present
in at least one of the two slides prepared.
2.3. Rectal biopsy (RB)
Rectal biopsies were performed in the endoscopy unit of the
National Liver Institute. Subjects from El-Gharbia governorate had
their RB performed in the Al-Mahalla City Charitable Medical
Centre for convenience. For this procedure, the patient was
positioned in the left lateral position with extension of the left knee
and ﬂexion of the right knee. A proctoscope with a light source was
inserted gently with lubricant into the rectum. Three to ﬁve
fragments of superﬁcial tissue were obtained with biopsy forceps.
Biopsies were taken from sites where small haemorrhages or other
suspicious lesions were seen. These tissue specimens were placed
between two glass slides and examined immediately under light
microscopy. All rectal biopsies were performed and analyzed by
trained clinical research fellows of the National Liver Institute,
Menouﬁa University, Egypt.
2.4. Sample size and power calculation
Prior data indicated that the infection rate among individuals in
the Nile Delta region, as determined using MSE, is 1.9%.6 If the true
infection rate of the same subjects increased to 3% by implementing
RB, 510 individuals would be required for screening to be able to
reject the null hypothesis that the infection rates for MSE and RB
subjects are equal. Analyses determined the minimum effect size
that may be detected with 90% power and type I error probability of
0.05 using Fisher’s exact test to evaluate the null hypothesis. Six
hundred and ﬁfty-one subjects were recruited to allow for
occasional individual preference to have a single diagnostic test
instead of having both tests and to confer a safe margin for dropouts.
The study was approved by the Ethics Committee of the
National Liver Institute and Menouﬁa University according to the
Declaration of Helsinki. Informed consent was obtained from all
adults recruited and from the guardians of all children enrolled.
3. Results
The study recruited individuals from different villages of three
governorates in the Nile Delta region of Lower Egypt. Fifty-ﬁve
Table 3
Group 3 screening test results: the relationship between microscopic stool
examination and the gold standarda
Gold standard test: RB+MSE
positive
Positive Negative Total
MSE
Positive 23 0 23
Negative 148 282 430
Total 171 282 453
MSE, microscopic stool examination; RB, rectal biopsy.
a The summation of rectal biopsy and stool examination was used as the gold
standard to determine the sensitivity and speciﬁcity of microscopic stool
examination: sensitivity = 23/(23 + 148) = 13.5%; speciﬁcity = 282/(282 + 0) = 100%;
positive predictive value = 23/23 = 100.0%; negative predictive value = 282/
430 = 65.6%; accuracy = (23 + 282)/453 = 67.3%.
Table 4
Group 3 screening test results: the relationship between rectal biopsy and the gold
standarda
Gold standard test: RB+MSE
positive
Positive Negative Total
RB
Positive 169 0 169
Negative 2 282 284
Total 171 282 453
MSE, microscopic stool examination; RB, rectal biopsy.
a The summation of rectal biopsy and stool examination was used as the gold
standard to determine the sensitivity and speciﬁcity of rectal biopsy: sensitivi-
ty = 169/(169 + 2) = 98.8%; speciﬁcity = 282/(282 + 0) = 100%; positive predictive
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466 male) with a clinically suspected infection were screened
using MSE, RB, or both. Adult subjects ranged in age from 18 to
61 years (mean 28.9 years), and 71.6% were male; the children
ranged in age from 7 to 9 years, and 51% were male.
The S. mansoni infection rate changed according to the method
of diagnosis. When conventional MSE was used alone in group 1
(adults) and group 4 (children), the infection rate was 11.7% (13/
111) and 3.6% (2/55), respectively. This increased substantially
with the use of RB alone for diagnosis (group 2): 40.6% (13/32)
(Table 1).
In group 3, each individual had both MSE and RB. The overall
positivity was 37.7% (171/453). Only 23 patients (23/453; 5.1%)
were positive by MSE, while 169/453 (37.3%) were positive by RB
(148 with RB only positive plus 21 patients with both MSE and RB
positive) (Figure 1). Of note, adding MSE to RB (group 3) did not
signiﬁcantly increase the prevalence compared to the use of RB
alone (group 2): 37.3% vs. 40.6%, respectively.
Table 2 shows the signiﬁcant statistical difference in prevalence
in group 3 according to the method of diagnosis. As expected, the
overall prevalence in females was lower than that in males (21.7%
vs. 42.7%).
To statistically translate these results, survey tables were
plotted to assess the sensitivity of MSE and RB. The sum of positive
cases for both MSE and RB was used as the gold standard assuming
a speciﬁcity of both tests of 100%. The results showed MSE to have a
sensitivity of 13.5%, a negative predictive value of 65.6%, and an
accuracy of 67.3%. In contrast, RB was found to have a sensitivity of
98.8%, negative predictive value of 99.3%, and accuracy of 99.5%
(Tables 3 and 4).Table 2
Sex-speciﬁc prevalence of Schistosoma mansoni by rectal biopsies and stool
examination in group 3
Sex No.
examined
Number (%) positive for Schistosoma mansoni p-Value
Both stool
and biopsies
positive
Stool
only
positive
Rectal
biopsies
only
positive
Total
positive
Male 347 12 (3.5%) 2 (0.6%) 134 (38.6%) 148 (42.7%) <0.01
Female 106 9 (8.5%) 0 (0%) 14 (13.2%) 23 (21.7%) <0.01
Total 453 21 (4.6%) 2 (0.4%) 148 (32.7%) 171 (37.7%)
Figure 1. Number of positive cases by each test for subjects in group 3. The overall
Schistosoma mansoni positivity was 37.7% (171/453), out of which only 23 patients
(5%) were positive by stool examination. Of 169 (37.3%) patients with a positive
rectal biopsy, 148 were positive only by rectal biopsy and 21 patients had both stool
examination and rectal biopsy positive. Overall negativity was 62.3% (282/453).
value = 169/169= 100.0%; negative predictive value = 282/284= 99.3%; accura-
cy = (169 + 282)/453= 99.5%.4. Discussion
These data suggest that the true prevalence in endemic
communities following mass treatment programmes may be
considerably underestimated. The conventional MSE method
failed to diagnose 86.5% (148/171) of positive cases. This
apparently striking result indicates that the use of simple
microscopic examination for the monitoring of infection is
ineffective because of the low sensitivity.
From the present results, it is believed that the mass treatment
strategy implemented by the WHO more than 10 years ago has led
to a new era of light Schistosoma infection for which simple MSE
can miss many cases. This would explain the signiﬁcant
contradiction in infection rates according to the method of
diagnosis in the present study. It would also clarify the high
prevalence found in the present study in which RB was
implemented, in comparison to the lower prevalence reported
by other studies in which various MSE methods were applied.8,9 To
the authors’ knowledge, this study is the ﬁrst to provide an
evaluation of the performance of the routinely used MSE and an
estimation of the prevalence of infection in Egypt following the
mass treatment ‘light infection era’. It also highlights the
importance and need for reliable and practical tests for the
diagnosis of S. mansoni to overcome the diagnostic dilemma
expected from ongoing mass treatment strategies.
Although the current data relate mainly to adults, MSE was also
evaluated in children aged 7–9 years, showing comparable results
to those obtained in adults using the same method of diagnosis
(Table 1). A similar underestimation of infection rates in school-
aged children as in adults is expected. Doctors and healthcare
workers should be aware that a negative stool examination does
not automatically mean that the patient is free of the disease.
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diagnosing patients with light infection. A light infection may have
substantial public health and economic impacts. It has been
assumed that a reduction in infection intensity has remained the
main objective of schistosomiasis control and morbidities.10
Schistosomiasis is a signiﬁcant chronic inﬂammatory disease that
contributes substantially to chronic morbidity whether of light or
heavy intensity.11 The relationship between light infection and
morbidity and/or mortality is not clear. The well-known infection-
associated advanced morbidities that occur late in infection, i.e.
liver ﬁbrosis, intestinal bleeding, urinary tract obstruction,
superinfection, and cancer, seem to represent only a small fraction
of Schistosoma infection-associated disease. Chronic complica-
tions, such as anaemia, under-nutrition, short stature or under-
weight, abdominal and pelvic pain, and possibly infertility, may
place a signiﬁcant health burden on affected individuals and
populations.12 Evidence suggests that the patient’s immune
response to the parasite and/or eggs indicates tissue inﬂammation
in schistosomiasis.13,14 This means that individuals who have a
light infection are still at signiﬁcant risk of schistosomiasis-
associated disease. Furthermore, it is known that children who are
exposed to their mother’s helminth infections in utero are born
with anti-parasite immune responses that polarize to either a
hyperactive or signiﬁcantly suppressed (i.e., hyperimmune or
tolerized) status. An important consequence of this skewing of the
immune response is that children with highly active anti-helminth
(Th2-type) immune responses are less responsive to routine
childhood vaccination against pathogens that require Th1 immu-
nity, such as tuberculosis.12
The beneﬁts of mass treatment are still questionable; the
results of the present study and others show that the beneﬁts of
these programmes as a deﬁnitive solution remain in doubt. These
programmes are unable to break the transmission cycle of
Schistosoma.9 Recurring low-level re-infection is likely to be
associated with subtle but persistent morbidity. Furthermore,
broad-scale chemotherapy alone will not reliably affect local levels
of parasite transmission and the consequent risk of re-infection
with Schistosoma.15,16 The cessation of drug treatment for even a
few years could result in the recurrence of high levels of
schistosome infection.17,18
The results of this study demonstrate that in adults, RB for the
detection of parasite eggs in tissue is the best currently available
diagnostic tool for active infection. Nevertheless, caution should be
applied. The inclusion of RB examination in the process of
diagnosing and monitoring human mass chemotherapy has
limitations. As a relatively invasive procedure, the lack of ﬁnancial
resources and need for well-trained medical staff will not easily
allow this option to replace the simple and quick MSE. The
relatively high operational costs compared with MSE make it an
unsuitable alternative test. Another disadvantage of RB is that the
intensity of the infection cannot be quantiﬁed. Furthermore, RB
requires relatively sophisticated equipment. In areas of high
endemicity, personnel with only basic training are available. More
importantly, establishing a RB unit would also require the
establishment of a well-standardized sterilization unit, otherwise
RB could become another source of serious blood-borne infection,
particularly hepatitis C and B, which are highly prevalent in the
region. In areas with a general lack of medical services, having a RB
may not be practical. The authors believe that a simple, cheap,
sensitive and speciﬁc assay for the routine diagnosis of schisto-
some infection is not yet available and is seriously needed.
In conclusion, current thinking on schistosomiasis should
change. The level of infection is actually higher than originallythought. The implementation of mass treatment programmes in
the last decade has resulted in a new era of light infection, for
which conventional parasitological methods for the diagnosis and
monitoring of infection are not effective. People who are stool-
negative for parasites cannot be assumed to be non-infected.
Improved diagnostic agents and therapeutic strategies should be
the main vital topic for further applied research on schistosomiasis.
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